CPB2

Across TCGA pan-cancer cohorts, CPB2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CPB2 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CPB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPB2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

COAD, LUAD, and LSCC are the cancer types where CPB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.877	1.000	.016	60	view →
LUAD	OS	Tertile	II,III,IV	0.430	0.852	.002	32	view →
LSCC	DFS	Median	II,III,IV	0.839	1.000	.006	16	view →
CCRCC	DFS	Median	All	0.883	0.632	.005	11	view →
HNSC	DFS	Quartile	All	1.000	0.918	.018	8	view →
PDAC	OS	Quartile	II,III,IV	0.723	0.984	.019	7	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CPB2–COAD (DFS)

Open the COAD breakdown →